InvestorsHub on MSN
Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy study
Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular ...
Durham-based Precision BioSciences, a gene-editing company, has received regulatory clearance to begin a clinical study of its potential treatment for Duchenne muscular dystrophy (DMD), a rare ...
DMD gene therapy faces challenges in safety, efficacy, and long-term outcomes, despite FDA approval of delandistrogene moxeparvovec. Future strategies focus on novel AAV capsids, dual/triple vector ...
Solid Biosciences (SLDB) stock retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne ...
"As we prepare to commence the Phase1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, we're excited to present new preclinical data highlighting its potential to deliver durable, long-term functional ...
Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed down) disorder. The condition is linked ...
Sen. Roger Wicker urges states to add Duchenne muscular dystrophy to newborn screening, after federal health officials back ...
Ifetroban significantly improved LVEF in DMD patients, showing a 5.4% improvement compared with propensity-matched natural history controls, with high-dose treatment yielding the most benefit. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results